Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology

@article{Dungarwalla2006LackOC,
  title={Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology},
  author={Moez Dungarwalla and Judith C. W. Marsh and Jennifer A Tooze and Geoff Lucas and Willem H Ouwehand and Ruth Pettengell and Clare E Dearden and E. C. Gordon Smith and Modupe O Elebute},
  journal={Annals of Hematology},
  year={2006},
  volume={86},
  pages={191-197}
}
We describe 11 patients with severe refractory autoimmune cytopenias treated with the anti-CD20 monoclonal antibody rituximab. Six patients had autoimmune neutropenia (AIN), two had pure red cell aplasia (PRCA), one had AIN and autoimmune haemolytic anaemia, one had AIN and immune thrombocytopaenia purpura (ITP) and one had PRCA and ITP. Rituximab was administered at a dose of 375 mg/m2 as an intravenous infusion weekly for 4 weeks. Six of eight patients with AIN and all three patients with… CONTINUE READING
21 Citations
43 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 43 references

New therapy with anti-CD20 antibody (rituximab) for autoimmune haemolytic anaemia

  • R Kakaiya
  • Blood Therap Med
  • 2003
Highly Influential
10 Excerpts

Sustained response of refractory chronic lymphocytic leukaemia in progression complicated by acute haemolytic anaemia anti CD20 monoclonal antibody

  • E Ianitto, E Ammatuna, C Marino, S Cirrincione, G Greco, G Mariani
  • Blood
  • 2002
Highly Influential
10 Excerpts

Re-treatment with a rituximab based therapy is highly effective in autoimmune haemolytic anaemia (AIHA) associated with chronic lymphocytic leukaemia (CLL)

  • NK Gupter
  • Blood
  • 2001
Highly Influential
10 Excerpts

Similar Papers

Loading similar papers…